• MHRA authorises Amarin’s heart drug Vazkepa pharmatimes
    April 23, 2021
    Amarin’s Vazkepa has received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a treatment to reduce the risk of cardiovascular (CV) events in high-risk patients.
  • Kesimpta and Vazkepa among latest CHMP recommendations pharmatimes
    February 01, 2021
    The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended 13 new medicines for approval in its latest meeting.
PharmaSources Customer Service